Zuhur, Sayid ShafiElbüken, GülşahYıldız, İsmailKadıoğlu, PınarErol, SelvinazŞahin, SerdarAltuntaş, Yüksel2022-05-112022-05-1120190018-50431439-4286https://doi.org/10.1055/a-0974-3991https://hdl.handle.net/20.500.11776/5732Recently, the Graves & apos; Recurrent Events After Therapy score (GREAT) was proposed as a useful tool to predict relapse before starting antithyroid drugs (ATD) in patients with Graves & apos; disease (GD). Therefore, we intended to assess the validity of the GREAT score in Turkish patients with GD, including patients who experienced a poorly controlled disease (multiple episodes of hyperthyroidism followed by euthyroidism or rarely hypothyroidism) during ATD dose titration. This is a retrospective multicenter study including 517 patients with the first episode of GD who were treated for at least 12 months. The patients were classified as relapse+poorly controlled disease (non-remission) and remission groups. During a median follow-up time of 35 months (12-144 months), 191 (37%) patients experienced a relapse, 136 (26.3%) a poorly controlled disease, and 190 (36.7%) remained in remission. Patients with non-remission disease tended to have significantly higher serum levels of TRAb, fT4, and fT3, and have larger goiter sizes on palpation at baseline, as compared with the remission group. Non-remission disease occurred in 12, 35, and, 53% of the patients falling into GREAT class I, II, and III, respectively (hazard ratio 2.56, 95% CI 2.02-3.51, p=0.012, and hazard ratio 3.54, 95% CI 2.12-5.91, p<0.001, for GREAT class II and III against class I, respectively). According to our study, the GREAT score is a useful tool to predict the risk of relapse as well as the occurrence of poorly controlled disease before starting treatment with ATDs.en10.1055/a-0974-3991info:eu-repo/semantics/openAccessGraves' diseaserelapseantithyroid drugsGREAT scorePredict RelapseDiseaseTherapyRiskManagementRecurrenceRemissionArticle5110627633Q3WOS:0004884724000012-s2.0-8507290437231499558Q2